{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:03:12Z","timestamp":1782741792298,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.nrl.2016.11.009","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:16:45Z","timestamp":1487290605000},"page":"386-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Acetato de eslicarbazepina en dolor neurop\u00e1tico, cefaleas y neuralgias craneales: Evidencia y experiencia"],"prefix":"10.1016","volume":"34","author":[{"given":"A.","family":"Alc\u00e1ntara Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.I.","family":"S\u00e1nchez Carnerero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2016.11.009_bib0200","unstructured":"Ficha t\u00e9cnica Zebinix\u00ae (acetato de eslicarbazepina) [consultado 6 Sept 2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000988\/WC500047225.pdf"},{"key":"10.1016\/j.nrl.2016.11.009_bib0205","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.nrl.2016.11.009_bib0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2012.03595.x","article-title":"Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbacepina in healthy volunteers","volume":"54","author":"Nunes","year":"2013","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2016.11.009_bib0215","doi-asserted-by":"crossref","first-page":"e00124","DOI":"10.1002\/prp2.124","article-title":"Eslicarbazepine acetate for the treatment of focal epilepsy: An update on its proposed mechanisms of action","volume":"3","author":"Soares-da-Silva","year":"2015","journal-title":"Pharmacol Res Perspect."},{"key":"10.1016\/j.nrl.2016.11.009_bib0220","unstructured":"Ficha t\u00e9cnica Tegretol\u00ae (carbamazepina) [consultado 6 Sept 2016]. Disponible en: https:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/39955\/FT_39955.pdf"},{"key":"10.1016\/j.nrl.2016.11.009_bib0225","unstructured":"Ficha t\u00e9cnica Trileptal\u00ae (oxcarbazepina) [consultado 6 Sept 2016]. Disponible en: https:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/63093\/FT_63093.pdf"},{"key":"10.1016\/j.nrl.2016.11.009_bib0230","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrl.2016.11.009_bib0235","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.2174\/092986711797200408","article-title":"Evaluation of anticonvulsants for possible use in neuropathic pain","volume":"18","author":"Waszkielewicz","year":"2011","journal-title":"Curr Med Chem."},{"key":"10.1016\/j.nrl.2016.11.009_bib0240","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1134-8046(09)73101-5","article-title":"Recomendaciones para el tratamiento del dolor neurop\u00e1tico","volume":"16","author":"Gonz\u00e1lez- Escalada","year":"2009","journal-title":"Rev Soc Esp Dolor."},{"key":"10.1016\/j.nrl.2016.11.009_bib0245","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.semerg.2015.09.007","article-title":"Actualizaci\u00f3n en el manejo de la neuralgia del trig\u00e9mino","volume":"42","author":"Alc\u00e1ntara Montero","year":"2016","journal-title":"Semergen."},{"key":"10.1016\/j.nrl.2016.11.009_bib0250","doi-asserted-by":"crossref","first-page":"223","DOI":"10.33588\/rn.6205.2015498","article-title":"Lacosamida y dolor neurop\u00e1tico, una revisi\u00f3n","volume":"62","author":"Alc\u00e1ntara-Montero","year":"2016","journal-title":"Rev Neurol."},{"key":"10.1016\/j.nrl.2016.11.009_bib0255","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007963.pub2","article-title":"Oxcarbazepine for neuropathic pain","author":"Zhou","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.nrl.2016.11.009_bib0260","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1213\/ANE.0000000000000953","article-title":"The efficacy of eslicarbazepine acetate in models of trigeminal, neuropathic, and visceral pain: The involvement of 5-HT1B\/1D serotonergic and CB1\/CB2 cannabinoid receptors","volume":"121","author":"Tomi\u0107","year":"2015","journal-title":"Anesth Analg."},{"key":"10.1016\/j.nrl.2016.11.009_bib0265","series-title":"Actas del 8th Biennial EFIC congress","article-title":"Efficacy and safety of eslicarbazepine acetate as therapy for subjects with painful diabetic neuropathy: Results of BIA-2093-206 phase II study","author":"Kress","year":"2013"},{"key":"10.1016\/j.nrl.2016.11.009_bib0270","unstructured":"Eslicarbazepine acetate as therapy in diabetic neuropathic pain [consultado 6 Sept 2016]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01129960?term=eslicarbazepine&rank=19"},{"key":"10.1016\/j.nrl.2016.11.009_bib0275","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.nrl.2014.10.013","article-title":"Experiencia en el tratamiento de la neuropat\u00eda diab\u00e9tica dolorosa con acetato de eslicarbacepina","volume":"31","author":"Garc\u00eda-Escriv\u00e0","year":"2016","journal-title":"Neurologia."},{"key":"10.1016\/j.nrl.2016.11.009_bib0280","first-page":"213","article-title":"Uso de eslicarbacepina en el dolor por neuropat\u00eda diab\u00e9tica","volume":"29","author":"Garc\u00eda-Escriv\u00e0","year":"2014","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0285","series-title":"Actas del 8th biennial EFIC congress","article-title":"Efficacy and safety of eslicarbazepine acetate as therapy for subjects with post-herpetic neuralgia: Results of BIA-2093-207 phase II study","author":"Kress","year":"2013"},{"key":"10.1016\/j.nrl.2016.11.009_bib0290","unstructured":"Eslicarbazepine acetate as therapy in post-herpetic neuralgia [consultado 6 Sept 2016]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01124097?term=eslicarbazepine&rank=18&sect=X70156"},{"key":"10.1016\/j.nrl.2016.11.009_bib0295","first-page":"a602","article-title":"Eslicarbazepine use in multiple sclerosis with refractory trigeminal neuralgia","volume":"6","author":"Gaber","year":"2013","journal-title":"BJMP."},{"key":"10.1016\/j.nrl.2016.11.009_bib0300","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1111\/papr.12261","article-title":"Eslicarbazepine acetate for a patient with highly resistant epicrania fugax","volume":"15","author":"Cuadrado","year":"2015","journal-title":"Pain Pract."},{"key":"10.1016\/j.nrl.2016.11.009_bib0305","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/0333102415620252","article-title":"SUNCT syndrome: A cohort of 15 Portuguese patients","volume":"36","author":"Ca\u00e7\u00e3o","year":"2016","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrl.2016.11.009_bib0310","first-page":"196","article-title":"Eslicarbacepina como tratamiento de un caso de epicrania fugax refractaria","volume":"29","author":"Aledo Serrano","year":"2014","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0315","first-page":"213","article-title":"Efectividad de la eslicarbacepina para el tratamiento de la neuralgia del trig\u00e9mino","volume":"29","author":"S\u00e1nchez Larsen","year":"2014","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0320","article-title":"Valoraci\u00f3n de la respuesta al tratamiento con acetato de eslicarbacepina en pacientes con neuralgias craneales","author":"Abril-Jaramillo","year":"2016","journal-title":"LXVII Reuni\u00f3n Anual de la Sociedad Espa\u00f1ola de Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0325","article-title":"Serie de casos cl\u00ednicos para evaluar la eficacia y tolerancia de acetato de eslicarbacepina en dolor neurop\u00e1tico","volume":"26","author":"Tena Mora","year":"2011","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0330","first-page":"213","article-title":"Acetato de eslicarbacepina como opci\u00f3n para el tratamiento del dolor neurop\u00e1tico: Serie de 10 casos","volume":"29","author":"Garc\u00eda Arguedas","year":"2014","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0335","article-title":"Experiencia con acetato de eslicarbacepina en el dolor neurop\u00e1tico","author":"Pagola Lorz","year":"2016","journal-title":"LXVII Reuni\u00f3n Anual de la Sociedad Espa\u00f1ola de Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0340","article-title":"Experiencia de eslicarbacepina en dolor neurop\u00e1tico refractario","author":"Bermejo Velasco","year":"2016","journal-title":"LXVII Reuni\u00f3n Anual de la Sociedad Espa\u00f1ola de Neurolog\u00eda."},{"key":"10.1016\/j.nrl.2016.11.009_bib0345","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000188819.45330.90","article-title":"Hyponatremia from oxcarbazepine and carbamazepine","volume":"65","author":"Dong","year":"2005","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2016.11.009_bib0350","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1528-1157.1994.tb02930.x","article-title":"Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review","volume":"35","author":"Van Amelsvoort","year":"1994","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2016.11.009_bib0355","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2215\/CJN.00170115","article-title":"Mild chronic hyponatremia in the ambulatory setting: Significance and management","volume":"10","author":"Rondon-Berrios","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nrl.2016.11.009_bib0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bone.2015.12.002","article-title":"The effect of chronic mild hyponatremia on bone mineral loss evaluated by retrospective national Danish patient data","volume":"84","author":"Kruse","year":"2016","journal-title":"Bone."},{"key":"10.1016\/j.nrl.2016.11.009_bib0365","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/j.1528-1167.2010.02660.x","article-title":"Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy","volume":"51","author":"Hal\u00e1sz","year":"2010","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2016.11.009_bib0370","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure."},{"key":"10.1016\/j.nrl.2016.11.009_bib0375","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eplepsyres.2012.07.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study","volume":"103","author":"Hufnagel","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.nrl.2016.11.009_bib0380","first-page":"47","article-title":"Experience with eslicarbazepine in patients with hiponatremia due to carbamazepine and oxcarbacepine","volume":"61","author":"Bermejo","year":"2015","journal-title":"Rev Neurol."},{"key":"10.1016\/j.nrl.2016.11.009_bib0385","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbacepina acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.nrl.2016.11.009_bib0390","article-title":"Consenso Delphi EPICON: Recomendaciones sobre el manejo adecuado del cambio a acetato de eslicarbacepina en epilepsia","author":"Villanueva","year":"2016","journal-title":"Neurologia."}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485317300014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485317300014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:10:50Z","timestamp":1759324250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485317300014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0213485317300014"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2016.11.009","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acetato de eslicarbazepina en dolor neurop\u00e1tico, cefaleas y neuralgias craneales: Evidencia y experiencia","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Neurolog\u00eda.","name":"copyright","label":"Copyright"}]}}